Bank of Montreal’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bank of Montreal’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,862	Closed	-$97.6K	–	3612
2025 Q3	$97.6K	Sell	12,862 -13,722	-52%	-$114K	﹤0.01%	2977
2025 Q2	$238K	Buy	26,584 +13,249	+99%	+$123K	﹤0.01%	2705
2025 Q1	$100K	Sell	13,335 -450	-3%	-$3.63K	﹤0.01%	2920
2024 Q4	$104K	Buy	13,785 +62	+0.5%	+$471	﹤0.01%	2942
2024 Q3	$105K	Hold	13,723	–	–	﹤0.01%	3232
2024 Q2	$85.1K	Buy	+13,723	New	+$75.7K	﹤0.01%	3284
2024 Q1	–	Sell	-26,279	Closed	-$161K	–	3894
2023 Q4	$161K	Sell	26,279 -122,244	-82%	-$708K	﹤0.01%	3214
2023 Q3	$1.02M	Buy	148,523 +106,125	+250%	+$762K	﹤0.01%	2054
2023 Q2	$329K	Buy	42,398 +3,238	+8%	+$26K	﹤0.01%	2878
2023 Q1	$334K	Sell	39,160 -8,302	-17%	-$79.9K	﹤0.01%	2719
2022 Q4	$592K	Sell	47,462 -1,533	-3%	-$19.1K	﹤0.01%	2517
2022 Q3	$632	Sell	48,995 -1,427	-3%	-$18.4K	﹤0.01%	2441
2022 Q2	$531	Sell	50,422 -5,663	-10%	-$58.4K	﹤0.01%	2651
2022 Q1	$922K	Buy	56,085 +9,895	+21%	+$159K	﹤0.01%	2405
2021 Q4	$637K	Sell	46,190 -28,383	-38%	-$376K	﹤0.01%	2216
2021 Q3	$1.15M	Buy	74,573 +21,806	+41%	+$344K	﹤0.01%	2403
2021 Q2	$831K	Sell	52,767 -5,082	-9%	-$69K	﹤0.01%	2602
2021 Q1	$601K	Sell	57,849 -24,230	-30%	-$250K	﹤0.01%	2527
2020 Q4	$617K	Buy	82,079 +56,138	+216%	+$289K	﹤0.01%	2591
2020 Q3	$91K	Sell	25,941 -5,188	-17%	-$22.2K	﹤0.01%	3128
2020 Q2	$172K	Buy	31,129 +29,910	+2,454%	+$119K	﹤0.01%	2809
2020 Q1	$2K	Sell	1,219 -18,679	-94%	-$51.4K	﹤0.01%	3837
2019 Q4	$68K	Buy	19,898 +9,236	+87%	+$23.2K	﹤0.01%	3680
2019 Q3	$31K	Buy	10,662 +443	+4%	+$1.38K	﹤0.01%	3842
2019 Q2	$39K	Buy	10,219 +9,219	+922%	+$55.5K	﹤0.01%	3807
2019 Q1	$8K	Sell	1,000 -1,544	-61%	-$13.2K	﹤0.01%	3926
2018 Q4	$20K	Buy	2,544 +790	+45%	+$6.14K	﹤0.01%	3637
2018 Q3	$14K	Buy	1,754 +55	+3%	+$369	﹤0.01%	3818
2018 Q2	$10K	Buy	1,699 +699	+70%	+$3.85K	﹤0.01%	3949
2018 Q1	$5K	Hold	1,000	–	–	﹤0.01%	3905
2017 Q4	$5K	Hold	1,000	–	–	﹤0.01%	3914
2017 Q3	$5K	Hold	1,000	–	–	﹤0.01%	3850
2017 Q2	$6K	Hold	1,000	–	–	﹤0.01%	3827
2017 Q1	$8K	Hold	1,000	–	–	﹤0.01%	3601
2016 Q4	$6K	Hold	1,000	–	–	﹤0.01%	3708
2016 Q3	$4K	Hold	1,000	–	–	﹤0.01%	3748
2016 Q2	$3K	Sell	1,000 -732	-42%	-$2.27K	﹤0.01%	3832
2016 Q1	$5K	Hold	1,732	–	–	﹤0.01%	3773
2015 Q4	$18K	Hold	1,732	–	–	﹤0.01%	3431
2015 Q3	$19K	Buy	1,732 +732	+73%	+$9.77K	﹤0.01%	3265
2015 Q2	$15K	Hold	1,000	–	–	﹤0.01%	3384
2015 Q1	$9K	Hold	1,000	–	–	﹤0.01%	3518
2014 Q4	$12K	Hold	1,000	–	–	﹤0.01%	3495
2014 Q3	$10K	Hold	1,000	–	–	﹤0.01%	3649
2014 Q2	$13K	Hold	1,000	–	–	﹤0.01%	3759
2014 Q1	$11K	Hold	1,000	–	–	﹤0.01%	3643
2013 Q4	$8K	Buy	+1,000	New	+$6.33K	﹤0.01%	3461

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of Montreal's BCRX Position: Q4 2025 in Review

Bank of Montreal sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 12,862 shares — an estimated $97.6K sold.

Bank of Montreal first reported a position in BCRX in Q4 2013 and held it in 47 quarters. The position peaked at $1.15M in Q3 2021. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Bank of Montreal reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bank of Montreal sold 12,862 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $97.6K.
Bank of Montreal first reported a position in BioCryst Pharmaceuticals in Q4 2013 and held it in 47 quarters.
Bank of Montreal's BioCryst Pharmaceuticals position peaked at $1.15M in Q3 2021.
273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Bank of Montreal's 13F filing for Q4 2025, filed 12 Feb 2026.